Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors

References

• Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Review Cell Dev Biol 2011; 27:585-610; PMID:21801013; http://dx.doi.org/10.1146/annurev-cellbio-092910-154234
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012; 13:189-203; PMID:22269907; http://dx.doi.org/10.1038/ngr3123
   PubMed Web of Science ®Google Scholar
• Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, Amon A. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007; 317:916-24; PMID:17702937; http://dx.doi.org/10.1126/science.1142210
   PubMed Web of Science ®Google Scholar
• Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE, Amon A. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008; 322:703-9; PMID:18974345; http://dx.doi.org/10.1126/science.1160058
   PubMed Web of Science ®Google Scholar
• Torres EM, Williams BR, Amon A. Aneuploidy: cells losing their balance. Genetics 2008; 179:737-46; PMID:18558649; http://dx.doi.org/10.1534/genetics.108.090878
   PubMed Web of Science ®Google Scholar
• Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G. Immunosurveillance against cancer-associated hyperploidy. Oncotarget 2012; 3:1270-1; PMID:23174699; http://dx.doi.org/10.18362/oncotarget.753
   PubMed Web of Science ®Google Scholar
• Senovilla L, Galluzzi L, Castedo M, Kroemer G. Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. Annal New York Acad Sci 2013; 1284:57-61; PMID:23651194; http://dx.doi.org/10.1111/nyas.12072
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature medicine 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
   PubMed Web of Science ®Google Scholar
• Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med (Berl) 2007; 85:1069-76; PMID:17891368; http://dx.doi.org/10.1007/s00109-007-0214-1
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Giordanetto F, Tesniere A, Vitale I, Martins I, Schlemmer F, Adjemian S, Zitvogel L, Kroemer G. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle 2009; 8:3971-7; PMID:19901557; http://dx.doi.org/10.4161/cc.8.23.10191
   PubMed Web of Science ®Google Scholar
• Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90:127-56; PMID:14710949; http://dx.doi.org/10.1016/S0065-230X(03)90004-2
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-61; PMID:12415255; http://dx.doi.org/10.1038/nrc928
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.smim.2006.03.002
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Review Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011; 89:216-24; PMID:20567250; http://dx.doi.org/10.1038/icb.2010.78
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol 2014; 5:106; PMID:24711808; http://dx.doi.org/10.3389/fimmu.2014.00106
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. Inter J Cancer J Inter du Cancer 2015; 136:1741-50; PMID:24615398; http://dx.doi.org/10.1002/ijc.28775
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198:557-67; PMID:12913096; http://dx.doi.org/10.1084/jem.20030788
   PubMed Web of Science ®Google Scholar
• Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S, Rivera P, Spaggiari GM, Dondero A, Carnemolla B, Reymond N et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005; 42:463-9; PMID:15607800; http://dx.doi.org/10.1016/j.molimm.2004.07.028
   PubMed Web of Science ®Google Scholar
• Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-503; PMID:19528259; http://dx.doi.org/10.1084/jem.20090681
   PubMed Web of Science ®Google Scholar
• Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013; 122:2935-42; PMID:23958951; http://dx.doi.org/10.1182/blood-2013-03-489054
   PubMed Web of Science ®Google Scholar
• Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-80; PMID:18394936; http://dx.doi.org/10.1016/j.immuni.2008.02.016
   PubMed Web of Science ®Google Scholar
• Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.org/10.1038/nature03884
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Quinones-Lombrana A, Lopez-Arbesu R, Lopez-Larrea C, Gonzalez S. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 2006; 281:30419-30; PMID:16901903; http://dx.doi.org/10.1074/jbc.M604868200
   PubMedGoogle Scholar
• Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013; 210:2057-69; PMID:24043758; http://dx.doi.org/10.1084/jem.20130783
   PubMed Web of Science ®Google Scholar
• Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012; 209:2409-22; PMID:23166357; http://dx.doi.org/10.1084/jem.20120565
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Huergo-Zapico L, Galvan JA, Rodrigo L, de Herreros AG, Astudillo A, Gonzalez S. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol 2013; 190:4408-19; PMID:23509364; http://dx.doi.org/10.4049/jimmunol.1202950
   PubMedGoogle Scholar
• Lopez-Soto A, Zapico LH, Acebes-Huerta A, Rodrigo L, Gonzalez S. Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition. Oncoimmunology 2013; 2:e25820; PMID:24244906; http://dx.doi.org/10.4161/onci.25820
   PubMed Web of Science ®Google Scholar
• Spies T. Regulation of NKG2D ligands: a purposeful but delicate affair. Nat Immunol 2008; 9:1013-5; PMID:18711442; http://dx.doi.org/10.1038/ni0908-1013
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
   PubMed Web of Science ®Google Scholar
• Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24:311-8; PMID:23787159; http://dx.doi.org/10.1016/j.cytogfr.2013.05.001
   PubMed Web of Science ®Google Scholar
• Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 2012; 55:7193-207; PMID:22827572; http://dx.doi.org/10.1021/jm300713s
   PubMed Web of Science ®Google Scholar
• Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307:935-9; PMID:15705855; http://dx.doi.org/10.1126/science.1101902
   PubMed Web of Science ®Google Scholar
• Chow J, Poon RY. DNA damage and polyploidization. Adv Exp Med Biol 2010; 676:57-71; PMID:20687469; http://dx.doi.org/10.1007/978-1-4419-6199-0_4
   PubMed Web of Science ®Google Scholar
• Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Frontiers Immunol 2014; 4:508; PMID:24432022; http://dx.doi.org/10.3389/fimmu.2013.00508
   PubMed Web of Science ®Google Scholar
• Sutherland J, Mannoni P, Rosa F, Huyat D, Turner AR, Fellous M. Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate. Human Immunol 1985; 12:65-73; PMID:2578442; http://dx.doi.org/10.1016/0198-8859(85)90344-1
   PubMed Web of Science ®Google Scholar
• Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981; 291:335-8; PMID:6164929; http://dx.doi.org/10.1038/291335a0
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87:21-7; PMID:12085250; http://dx.doi.org/10.1038/sj.bjc.6600347
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Inter J Cancer 2013; 133:624-36; PMID:23364915; http://dx.doi.org/10.1002/ijc.28070
   PubMed Web of Science ®Google Scholar
• Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunology, Immunother 2000; 49:181-5; PMID:10941900; http://dx.doi.org/10.1007/s002620000122
   PubMed Web of Science ®Google Scholar
• Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004; 32:4358-67; PMID:15314206; http://dx.doi.org/10.1093/nar/gkh744
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009; 28:2370-82; PMID:19430493; http://dx.doi.org/10.1038/onc.2009.117
   PubMedGoogle Scholar